-
Mashup Score: 97USPSTF Recommendation: Screening for Breast Cancer - 12 day(s) ago
This 2024 Recommendation Statement from the US Preventive Services Task Force recommends biennial screening mammography for women aged 40 to 74 years (B recommendation) and concludes that evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 years…
Source: jamanetwork.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1PRIME® Virtual Meeting - Taking Charge of My Breast Cancer Journey: A Patient Town Hall - 12 day(s) ago
Join us for an interactive Town Hall for patients with breast cancer and their caregivers!This program is designed to equip breast cancer patients and…
Source: primeinc.orgCategories: General Medicine News, NursingTweet
-
Mashup Score: 2Preoperative single-dose camrelizumab and/or microwave ablation in women with early-stage breast cancer: A window-of-opportunity trial - 12 day(s) ago
Innovative treatments are still needed to reduce metastatic disease for early-stage breast cancer. Pan et al. found that local microwave ablation combined with camrelizumab showed a favorable local effect and systemic immune response in the treatment of early-stage breast cancer, and the long-term effect of this strategy is worth investigating.
Source: www.cell.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4Collection Details : Oncology Times - 13 day(s) ago
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Commentary on: Yao MM, Vy VPT, Chen TH, Hsu HH, Hsu GC, Lee CS, Lin LJ, Chia SL, Wu CC, Chan WP, Yen AM. Performance measures of 8,169,869 examinations in the National Breast Cancer Screening Program in Taiwan, 2004-2020. BMC Med. 2023 Dec 15;21(1):497. doi: 10.1186/s12916-023-03217-7. ### Implications for practice and research Breast cancer continues to be a major public health concern, affecting millions of women globally each year.1 An early diagnosis using mammography is crucial for a successful treatment and better quality of life.2 Many women still do not receive regular mammography screening due to factors such as lack of awareness or limited access.3 Yao et al evaluated the impact of Taiwan’s Breast Cancer Screening …
Source: ebn.bmj.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 39
For decades, treatment for cancer was a blunt tool — everyone got the same, left to fight for their life chances against sometimes impossible odds. That is changing. Today, a breakthrough at a London research lab could lead to personalised treatments — in this case for advanced breast cancer.
Source: www.standard.co.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Collection Details : Oncology Times - 14 day(s) ago
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Collection Details : Oncology Times - 15 day(s) ago
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Women in their 40s and older should get a mammogram every other year, according to official new guidelines from the U.S. Preventive Services Task Force.
Source: www.nbcnews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
Overall, GHS and quality of life were maintained for both treatment groups, with prespecified PRO variables favouring trastuzumab deruxtecan over treatment of physician’s choice, suggesting that despite a longer treatment duration, there was no detrimental impact on patient health-related quality of life with trastuzumab deruxtecan. When considered with efficacy and safety data from DESTINY-Breast02, these results support the overall benefit of trastuzumab deruxtecan for patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab emtansine.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Most viewed in the last 7 days from @JAMA_current: New USPSTF guidelines recommends all women undergo routine #breastcancer screening every other year beginning at age 40, an update from the 2016 recommendation to start at age 50. https://t.co/lRQEU6s0Q4 https://t.co/860jxCkfjE